AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30716509 — intervention group
Group type: EXPERIMENTAL
Intervention: SI! Program (curriculum‐based educational program over 3 or 6 academic years)
Number of subjects: 1770
Study 30716509 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum (control group)
Number of subjects: 1770
Study 30716509 — intervention group
Group type: EXPERIMENTAL
Intervention: SI! Program
Number of subjects: 1770
Study 30286760 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) 70 ml (6.5 mmol NO3‐)
Number of subjects: 12
Study 30286760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 26712474 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscheduled health care visits for asthma or use of oral corticosteroids in the previous year
Number of subjects: 718
Study 26712474 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in 1 second (FEV1)
Number of subjects: 718
Study 26712474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-bronchodilator ratios of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC)
Number of subjects: 718
Study 26712474 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom scores on validated questionnaires
Number of subjects: 718
Study 25161182 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 47
Study 25161182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 21966995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg (with optional dose escalation to 8 mg at week 4)
Number of subjects: 943
Study 21966995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg
Number of subjects: 943
Study 21966995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 943
Study 20300709 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention programs and interventions in the field of drug abuse
Number of subjects: 0
Study 20300709 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized evaluation
Number of subjects: 0
Study 20300709 — intervention group
Group type: COMPARATOR
Intervention: Pre‐post assessment
Number of subjects: 0
Study 20300709 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational approach for evaluation
Number of subjects: 0
Study 17950801 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dabigatran plus aspirin
Number of subjects: 502
Study 17950801 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg dabigatran
Number of subjects: 502
Study 17950801 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dabigatran
Number of subjects: 502
Study 17950801 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dabigatran
Number of subjects: 502
Study 17950801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (50 mg, 150 mg, 300 mg)
Number of subjects: 502
Study 17950801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 502
Study 15973094 — intervention group
Group type: COMPARATOR
Intervention: No axillary dissection
Number of subjects: 219
Study 15973094 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 219
Study 12089124 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler (MDI) plus spacer (400 microg, 4 puffs)
Number of subjects: 12
Study 12089124 — intervention group
Group type: COMPARATOR
Intervention: Small Volume Nebuliser (SVN) (0.15 mg/kg)
Number of subjects: 12
Study 12089124 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (MDI plus spacer and SVN)
Number of subjects: 12
Study 10480520 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadal androgens (testosterone and androstenedione)
Number of subjects: 28
Study 7497601 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 42 mg/m2 per day
Number of subjects: 18
Study 7497601 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 35 mg/m2 per day
Number of subjects: 18
Study 7497601 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (all doses)
Number of subjects: 18
Study 7497601 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 18
Study 1645990 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic solutions with added sodium bicarbonate
Number of subjects: 0
Study 1645990 — intervention group
Group type: COMPARATOR
Intervention: Anesthetic solutions without added sodium bicarbonate
Number of subjects: 0
Study 7021261 — intervention group
Group type: EXPERIMENTAL
Intervention: Flufenamic acid, 100 mg, four times daily
Number of subjects: 40
Study 7021261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7021261 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (up to 8 x 500 mg daily)
Number of subjects: 40
Study 7021261 — intervention group
Group type: EXPERIMENTAL
Intervention: Flufenamic acid
Number of subjects: 40
Study 30266874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 1169
Study 30266874 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient or outpatient episodes of diarrhoea and inpatient severe pneumonia during follow-up
Number of subjects: 1169
Study 30266874 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature birth and not being cared by the biological parent
Number of subjects: 1169
Study 30266874 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in mid-upper arm circumference and weight-for-age
Number of subjects: 1169
Study 30266874 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in weight-for-height
Number of subjects: 1169
Study 30266874 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to improve dietary quality and prevent illness
Number of subjects: 1169
Study 27524815 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized nutrition advice
Number of subjects: 1269
Study 27524815 — intervention group
Group type: COMPARATOR
Intervention: Conventional dietary advice (control)
Number of subjects: 1269
Study 27552352 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Power Pain Threshold (HPPT) ultrasound therapy
Number of subjects: 61
Study 27552352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 61
Study 27552352 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study 24956454 — intervention group
Group type: EXPERIMENTAL
Intervention: Reader + DST (n = 16)
Number of subjects: 31
Study 24956454 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 15)
Number of subjects: 31
Study 22993332 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 573
Study 22993332 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (PA)
Number of subjects: 573
Study 18704569 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-pass transjugular liver biopsy (TJLB)
Number of subjects: 92
Study 18704569 — intervention group
Group type: COMPARATOR
Intervention: Three-pass transjugular liver biopsy (TJLB)
Number of subjects: 92
Study 18704569 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-pass TJLB with cassette
Number of subjects: 92
Study 18704569 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-pass TJLB without cassette
Number of subjects: 92
Study 17305652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 mg for 2 months and then 8 mg daily
Number of subjects: 555
Study 17305652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 17305652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG)
Number of subjects: 555
Study 15085323 — intervention group
Group type: EXPERIMENTAL
Intervention: povidone-iodine 10% (PVP-iodine)
Number of subjects: 119
Study 15085323 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorhexidine 0.5%/propanol 70%
Number of subjects: 119
Study 15085323 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorhexidine 0.5%/propanol 70% followed by PVP-iodine 10%
Number of subjects: 119
Study 12029412 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow endotracheal surfactant infusion
Number of subjects: 14
Study 12029412 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of surfactant
Number of subjects: 14
Study 9836210 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms.kg‐1 followed by propofol 4 mg.kg‐1 with lignocaine 0.2 mg.kg‐1
Number of subjects: 40
Study 9836210 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram.kg‐1 followed by propofol 4 mg.kg‐1 with lignocaine 0.2 mg.kg‐1
Number of subjects: 40
Study 9836210 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil and Remifentanil
Number of subjects: 40
Study 8136941 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine early amniotomy
Number of subjects: 1463
Study 8136941 — intervention group
Group type: COMPARATOR
Intervention: Delayed amniotomy (intact membranes)
Number of subjects: 1463
Study 2508524 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 7
Study 2508524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 962994 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy and specific active immunotherapy (C+I)
Number of subjects: 56
Study 962994 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (C)
Number of subjects: 56
Study 31233541 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant flooring (2.54 cm SmartCells)
Number of subjects: 184
Study 31233541 — intervention group
Group type: COMPARATOR
Intervention: Rigid control flooring (2.54 cm plywood)
Number of subjects: 184
Study 27717706 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D direct visualization
Number of subjects: 15
Study 27717706 — intervention group
Group type: COMPARATOR
Intervention: Standard 2D laparoscopy
Number of subjects: 15
Study 25448491 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy plus lenalidomide (DLBCL-len)
Number of subjects: 329
Study 25448491 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (DLBCL-c)
Number of subjects: 329
Study 25448491 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lenalidomide-induced hypothyroidism
Number of subjects: 329
Study 23883653 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation on top of medical treatment
Number of subjects: 60
Study 23883653 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 60
Study 21545769 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group fitted with Siemens Artis 2 SP BTE hearing aids, transitioning to NAL-RP targets over 15 weeks.
Number of subjects: 23
Study 21545769 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained initial settings throughout the study.
Number of subjects: 23
Study 19032600 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 14
Study 19032600 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated eccentric exercise
Number of subjects: 14
Study 19032600 — intervention group
Group type: EXPERIMENTAL
Intervention: First-bout eccentric exercise
Number of subjects: 14
Study 16715187 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium mixed with 1:3 iohexol
Number of subjects: 42
Study 16715187 — intervention group
Group type: COMPARATOR
Intervention: Iodine (iohexol) only
Number of subjects: 42
Study 15367069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print and video (TPV) intervention
Number of subjects: 587
Study 15367069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print and video (TPV) intervention among those 50 and older (n = 287)
Number of subjects: 587
Study 15367069 — intervention group
Group type: COMPARATOR
Intervention: Lay health advisor (LHA) intervention
Number of subjects: 587
Study 11742335 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive video-assisted thyroidectomy (MIVAT)
Number of subjects: 49
Study 11742335 — intervention group
Group type: COMPARATOR
Intervention: Conventional thyroidectomy (CT)
Number of subjects: 49
Study 9006472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse run clinic
Number of subjects: 251
Study 9006472 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 251
Study 8235664 — intervention group
Group type: EXPERIMENTAL
Intervention: 10MTX (10 mg/M2/wk)
Number of subjects: 520
Study 8235664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 8235664 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (10 mg/kg/d)
Number of subjects: 520
Study 8235664 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (6 mg/kg/d)
Number of subjects: 520
Study 8235664 — intervention group
Group type: COMPARATOR
Intervention: Auranofin (0.15 to 0.20 mg/kg/d)
Number of subjects: 520
Study 8235664 — intervention group
Group type: COMPARATOR
Intervention: 5MTX (5 mg/M2/wk)
Number of subjects: 520
Study 3316278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 82
Study 3316278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 31362999 — intervention group
Group type: EXPERIMENTAL
Intervention: Black garlic with Lactobacillus bulgaricus (BG)
Number of subjects: 226
Study 31362999 — intervention group
Group type: COMPARATOR
Intervention: Black garlic (CG)
Number of subjects: 226
Study 27803033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, cisplatin, and paclitaxel (bevacizumab 15 mg/kg, cisplatin 50 mg/m2, paclitaxel 135 mg/m2 over 24 h or 175 mg/m2 over 3 h) administered every 3 weeks until disease progression or unacceptable toxicity.
Number of subjects: 7
Study 25475358 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 10 mg with acetaminophen 1000 mg
Number of subjects: 90
Study 25475358 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 10 mg with acetaminophen 500 mg
Number of subjects: 90
Study 25475358 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 5 mg with acetaminophen 1000 mg
Number of subjects: 90
Study 24067392 — intervention group
Group type: EXPERIMENTAL
Intervention: Half a gold kiwifruit (Actinidia Chinensis var. Hort 16A) per day
Number of subjects: 36
Study 24067392 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C tablet (50 mg)
Number of subjects: 36
Study 21565490 — intervention group
Group type: EXPERIMENTAL
Intervention: OFF (oxaliplatin, folinic acid, and 5-fluorouracil)
Number of subjects: 46
Study 21565490 — intervention group
Group type: COMPARATOR
Intervention: BSC (Best Supportive Care)
Number of subjects: 46
Study 21565490 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM-OFF (Gemcitabine followed by OFF)
Number of subjects: 46
Study 21565490 — intervention group
Group type: COMPARATOR
Intervention: GEM-BSC (Gemcitabine followed by BSC)
Number of subjects: 46
Study 18270132 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate/aspartate supplementation
Number of subjects: 70
Study 18270132 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (Control)
Number of subjects: 70
Study 17138710 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical caries removal (CMCR)
Number of subjects: 50
Study 17138710 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (TM)
Number of subjects: 50
Study 15575172 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol (50 microg/gm cream applied twice daily)
Number of subjects: 18
Study 15575172 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol (ointment)
Number of subjects: 18
Study 15575172 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol
Number of subjects: 18
Study 11052493 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drug, acetaminophen, or placebo for 2 weeks
Number of subjects: 53
Study 11052493 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased pain
Number of subjects: 53
Study 11052493 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased pain
Number of subjects: 53
Study 11052493 — intervention group
Group type: EXPERIMENTAL
Intervention: Unchanged pain
Number of subjects: 53
Study 9352449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral annulus calcification
Number of subjects: 1219
Study 9352449 — intervention group
Group type: COMPARATOR
Intervention: Control group (without mitral annulus calcification)
Number of subjects: 1219
Study 9352449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension and carotid atheroma
Number of subjects: 1219
Study 8257447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg daily)
Number of subjects: 24
Study 3910706 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (600 mg/day, 2 days before and 6 days after surgery)
Number of subjects: 85
Study 3910706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 31657587 — intervention group
Group type: EXPERIMENTAL
Intervention: TT (teacher-training and coaching program without parental-awareness meetings)
Number of subjects: 0
Study 31657587 — intervention group
Group type: COMPARATOR
Intervention: TTPA (teacher-training and coaching program with parental-awareness meetings)
Number of subjects: 0
Study 31657587 — intervention group
Group type: EXPERIMENTAL
Intervention: TT and TTPA
Number of subjects: 0
Study 29381796 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-6 polyunsaturated fatty acids (PUFAs)
Number of subjects: 36
Study 29381796 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 36
Study 26395209 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-supported group-based Otago exercise programme (OEP)
Number of subjects: 51
Study 24571961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Consultancy (CAC)
Number of subjects: 20
Study 24571961 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 20
Study 23020133 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP (thrombin receptor activating peptide)
Number of subjects: 23
Study 23020133 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP (adenosine diphosphate)
Number of subjects: 23
Study 23020133 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP (collagen-related peptide)
Number of subjects: 23
Study 23020133 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve
Number of subjects: 23
Study 23020133 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-maximal response
Number of subjects: 23
Study 20124218 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 6-thioguanine (TG)
Number of subjects: 2027
Study 20124218 — intervention group
Group type: COMPARATOR
Intervention: Oral 6-mercaptopurine (MP)
Number of subjects: 2027
Study 18481439 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (shortwave diathermy, exercise, naproxen, activity modification)
Number of subjects: 162
Study 18481439 — intervention group
Group type: COMPARATOR
Intervention: Group B (shortwave diathermy, exercise, naproxen)
Number of subjects: 162
Study 15700173 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% gastrografin
Number of subjects: 24
Study 15700173 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% gastrografin
Number of subjects: 24
Study 15700173 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% gastrografin
Number of subjects: 24
Study 15700173 — intervention group
Group type: COMPARATOR
Intervention: 0% gastrografin
Number of subjects: 24
Study 12161768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25-100 mg)
Number of subjects: 242
Study 12161768 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine (40 mg)
Number of subjects: 242
Study 12828169 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (25 mg intravenously)
Number of subjects: 45
Study 12828169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg intravenously)
Number of subjects: 45
Study 12828169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 45
Study 8792442 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg low dose aspirin
Number of subjects: 12
Study 8792442 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg low dose aspirin
Number of subjects: 12
Study 8792442 — intervention group
Group type: EXPERIMENTAL
Intervention: 80mg low dose aspirin
Number of subjects: 12
Study 8792442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1639047 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 g salmon daily for 40 days
Number of subjects: 9
Study 1639047 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (BD)
Number of subjects: 9
Study 6735964 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg daily tobramycin
Number of subjects: 8
Study 6735964 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg daily tobramycin
Number of subjects: 8
Study 6735964 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg daily tobramycin with 1000 mg neomycin
Number of subjects: 8
Study 31766627 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate for gestational age (AGA) birth weight
Number of subjects: 747
Study 31766627 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive body weight >4000 g
Number of subjects: 747
Study 31766627 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater body length
Number of subjects: 747
Study 29137837 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based learning (GBL) intervention (Tapamole)
Number of subjects: 60
Study 29137837 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet intervention
Number of subjects: 60
Study 27563681 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management (DSM)
Number of subjects: 400
Study 24527599 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurac training combined with conventional treatments for 2 weeks
Number of subjects: 60
Study 24527599 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments (cervical traction, manual therapy, electrical therapy) for 2 weeks
Number of subjects: 60
Study 22569241 — intervention group
Group type: EXPERIMENTAL
Intervention: 130 mg dehydroepiandrosterone (DHEA)
Number of subjects: 16
Study 22569241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20491724 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonnic nicotine mouth spray (1 mg/spray)
Number of subjects: 47